Gabriel Cheung, Director of Antibody Technologies
- Director of Antibody Technologies
- Ph.D., University of Minnesota, Twin Cities
The Antibodies Technologies research group is interested in developing novel technologies around antibodies to promote:
- Better ways to generate/identify monoclonal antibodies.
- Better ways to modify/enhance monoclonal antibodies.
- Better ways to apply monoclonal antibodies.
Over the years, Dr. Cheung has been focused on developing next generation antibody discovery platforms. The development of the XMT® antibody discovery platform revolutionized the way we captured and identified antigen specific rabbit monoclonal antibodies. This platform allowed Cell Signaling Technology (CST) to develop some of the highest quality rabbit monoclonal antibodies for the life science research community and to provide the best in class reagents for diagnostics.
Recently, Dr. Cheung group has been focusing on developing NG-XMT™, a powerful novel proteomic driven antibody discovery platform. This new technology, for the first time, allows immunologists to track changes of circulating antibodies in immunized animals. This technology opens a new door for immunologists to understand circulating antibodies evolution and dynamics during humoral immune response against foreign antigens. Very importantly, the technology can also be applied to therapeutic antibody development.
Other areas of research activities also include: antibody engineering, antibody expression, and basic B cell immunology. The Antibody Technologies group's ultimate goal is to translate research findings into the best customer experience with CST™ antibodies in research, diagnostics, and therapeutics.
- Cheung WC, Beausoleil SA, Zhang X, Sato S, Schieferl SM, Wieler JS, Beaudet JG, Ramenani RK, Popova L, Comb MJ, Rush J, Polakiewicz RD (2012) A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol. 30(5), 447–52.
- Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ (2009) Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin. Cancer Res. 15(9), 3023-8.
- Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC, Janz S (2005) Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 65(4), 1306-15.
- Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S (2004) Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J. Clin. Invest. 113(12), 1763-73.